112 related articles for article (PubMed ID: 19203502)
1. The role of complement activation, detected by urinary C5b-9 and urinary factor H, in the excretion of urinary albumin in cisplatin nephropathy.
Fuke Y; Fujita T; Satomura A; Endo M; Matsumoto K
Clin Nephrol; 2009 Feb; 71(2):110-7. PubMed ID: 19203502
[TBL] [Abstract][Full Text] [Related]
2. Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function.
Onda K; Ohsawa I; Ohi H; Tamano M; Mano S; Wakabayashi M; Toki A; Horikoshi S; Fujita T; Tomino Y
BMC Nephrol; 2011 Nov; 12():64. PubMed ID: 22111871
[TBL] [Abstract][Full Text] [Related]
3. Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy.
Endo M; Fuke Y; Tamano M; Hidaka M; Ohsawa I; Fujita T; Ohi H
Nephron Clin Pract; 2004; 97(4):c147-53. PubMed ID: 15331938
[TBL] [Abstract][Full Text] [Related]
4. Elevated urinary excretion of the C5b-9 complex in membranous nephropathy.
Schulze M; Donadio JV; Pruchno CJ; Baker PJ; Johnson RJ; Stahl RA; Watkins S; Martin DC; Wurzner R; Gotze O
Kidney Int; 1991 Sep; 40(3):533-8. PubMed ID: 1787650
[TBL] [Abstract][Full Text] [Related]
5. Properdin has an ascendancy over factor H regulation in complement-mediated renal tubular damage.
Nagamachi S; Ohsawa I; Suzuki H; Sato N; Inoshita H; Hisada A; Honda D; Shimamoto M; Shimizu Y; Horikoshi S; Tomino Y
BMC Nephrol; 2014 May; 15():82. PubMed ID: 24885016
[TBL] [Abstract][Full Text] [Related]
6. [Combination effects of cis-dichlorodiammineplatinum (II) and sodium thiosulfate on renal dysfunction].
Hirosawa A; Sakai S; Iizuka K; Niitani H; Hayashibara K; Tsuboi E
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2870-5. PubMed ID: 3662543
[TBL] [Abstract][Full Text] [Related]
7. [Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer].
Soejima A; Inoue T; Suzuki M; Waku M; Nakabayashi K; Kitamoto K; Nagasawa T
Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):801-6. PubMed ID: 1479719
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of urinary factor H excretion in patients with idiopathic membranous nephropathy].
Endo M; Fuke Y; Ohi H; Satomura A; Fukuda N; Fujita T; Matsumoto K
Nihon Jinzo Gakkai Shi; 2007; 49(5):499-504. PubMed ID: 17695812
[TBL] [Abstract][Full Text] [Related]
9. High levels of urinary complement proteins are associated with chronic renal damage and proximal tubule dysfunction in immunoglobulin A nephropathy.
Wen L; Zhao Z; Wang Z; Xiao J; Birn H; Gregersen JW
Nephrology (Carlton); 2019 Jul; 24(7):703-710. PubMed ID: 30141239
[TBL] [Abstract][Full Text] [Related]
10. Complement activation and kidney injury molecule-1-associated proximal tubule injury in severe preeclampsia.
Burwick RM; Easter SR; Dawood HY; Yamamoto HS; Fichorova RN; Feinberg BB
Hypertension; 2014 Oct; 64(4):833-8. PubMed ID: 24958504
[TBL] [Abstract][Full Text] [Related]
11. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
12. Proteinuria is accompanied by intratubular complement activation and apical membrane deposition of C3dg and C5b-9 in kidney transplant recipients.
Isaksson GL; Nielsen MB; Hinrichs GR; Krogstrup NV; Zachar R; Stubmark H; Svenningsen P; Madsen K; Bistrup C; Jespersen B; Birn H; Palarasah Y; Jensen BL;
Am J Physiol Renal Physiol; 2022 Feb; 322(2):F150-F163. PubMed ID: 34927448
[TBL] [Abstract][Full Text] [Related]
13. The temporal relationship between urinary C5b-9 and C3dg and clinical parameters in human membranous nephropathy.
Coupes BM; Kon SP; Brenchley PE; Short CD; Mallick NP
Nephrol Dial Transplant; 1993; 8(5):397-401. PubMed ID: 8393542
[TBL] [Abstract][Full Text] [Related]
14. Urinary properdin excretion is associated with intrarenal complement activation and poor renal function.
Siezenga MA; van der Geest RN; Mallat MJ; Rabelink TJ; Daha MR; Berger SP
Nephrol Dial Transplant; 2010 Apr; 25(4):1157-61. PubMed ID: 19934084
[TBL] [Abstract][Full Text] [Related]
15. Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study.
Shoji S; Hosojima M; Kabasawa H; Kondo R; Miura S; Watanabe S; Aoki N; Kaseda R; Kuwahara S; Tanabe N; Hirayama Y; Narita I; Kikuchi T; Kagamu H; Saito A
BMC Cancer; 2019 Dec; 19(1):1170. PubMed ID: 31791266
[TBL] [Abstract][Full Text] [Related]
16. Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum(II).
Ikeda H; Nagashima K; Okumura H; Takahashi A; Matsuyama S; Nagamachi Y
Eur J Surg Oncol; 1988 Feb; 14(1):17-20. PubMed ID: 3278937
[TBL] [Abstract][Full Text] [Related]
17. [Prophylactic effect of ulinastatin on cisplatin-induced renal disorders in lung cancer patients].
Horiguchi T; Kasahara J; Ogura K; Handa M; Hosoda H; Shakato A; Tachikawa S; Sato M; Suetsugu S; Umeda H
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Jan; 30(1):12-9. PubMed ID: 1625386
[TBL] [Abstract][Full Text] [Related]
18. Renal C3 synthesis in idiopathic membranous nephropathy: correlation to urinary C5b-9 excretion.
Montinaro V; Lopez A; Monno R; Cappiello V; Manno C; Gesualdo L; Schena FP
Kidney Int; 2000 Jan; 57(1):137-46. PubMed ID: 10620195
[TBL] [Abstract][Full Text] [Related]
19. [Effects of combination chemotherapy with cis-diamminedichloroplatinum (II) (CDDP) on renal function in patients with urogenital malignancies].
Kawamura J; Hida S; Higashi Y; Yamauchi T; Soeda A; Yoshida O
Hinyokika Kiyo; 1985 Feb; 31(2):207-21. PubMed ID: 4040315
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer.
Miyoshi T; Misumi N; Hiraike M; Mihara Y; Nishino T; Tsuruta M; Kawamata Y; Hiraki Y; Kozono A; Ichiki M
Biol Pharm Bull; 2016; 39(12):2009-2014. PubMed ID: 27904042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
